title: [Cardioprotective effect of erythropoietin preparations in patients with chronic renal failure].
abstract: OBJECTIVE
  To investigate effects of early correction of anemia on the rate of cardiovascular complications and survival on regular hemodialysis (RHD).
  
  
  METHODS
  Eighty patients with chronic renal failure (CRF) on regular hemodialysis entered two groups: group 1 with hemoglobin (Hb) < 80 g/l (n = 36) and group 2 with Hb > 100 g/l (n = 44). 90% patients of group 2 were treated for renal anemia for 6-8 months of predialysis CRF. When placed on RHD, group 1 started therapy with epoetin, 39 patients of group 2 continued epoetin treatment.
  
  
  RESULTS
  Patients of group 2 had a higher rate of eccentric left ventricular hypertrophy (LVH) with reduced ejection fraction and development of congestive cardiac failure and coronary heart disease. Eccentric LVH in group 1 patients regressed only in 80% when the patients were on hemodialysis and received epoetin for correction of anemia. Overall cardiac death in group 1 was twice that of group 2 patients.
  
  
  CONCLUSIONS
  Early correction of anemia led to a 50% increase in 5-year survival. This fact can be explained with inhibited progression of eccentric LVH.
authors.forename: A Iu
authors.initials: AIu
authors.lastname: Nikolaev
authors.forename: V M
authors.initials: VM
authors.lastname: Ermolenko
authors.forename: L Iu
authors.initials: LIu
authors.lastname: Milovanova
authors.forename: Iu S
authors.initials: IuS
authors.lastname: Milovanov
mesh_terms: D000328:Adult; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D002316:Cardiotonic Agents / Q000008:administration & dosage*; D016022:Case-Control Studies; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000008:administration & dosage*; D005260:Female; D006397:Hematinics / Q000008:administration & dosage*; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000188:drug therapy / Q000209:etiology / Q000401:mortality; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D006435:Renal Dialysis; D016277:Ventricular Function, Left / Q000187:drug effects
chemical_list: D002316:Cardiotonic Agents; D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa